BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference

Rhea-AI Summary

BridgeBio Pharma, a biopharmaceutical company focused on genetic diseases and cancers, announced its management team's participation in the Bank of America Securities Healthcare Conference on May 11, 2022, at 7:40 pm ET. Investors can access the live webcast on the 'Events & Presentations' page of BridgeBio's website, with a replay available for 90 days post-event. Founded in 2015, BridgeBio aims to develop transformative medicines for patients with genetic conditions, showcasing a commitment to genetic medicine.

News Market Reaction – BBIO

-13.88%

-13.88% Session move

In the trading session that priced this news, BBIO declined 13.88%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will participate in the Bank of America Securities Healthcare Conference in Las Vegas, NV on Wednesday, May 11^th at 7:40 pm ET.

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.

BridgeBio Contact:
Grace Rauh
Grace.rauh@bridgebio.com
(917) 232-5478

FAQ

What event is BridgeBio Pharma participating in on May 11, 2022?

BridgeBio Pharma will participate in the Bank of America Securities Healthcare Conference on May 11, 2022.

What time is the Bank of America Securities Healthcare Conference presentation?

The presentation is scheduled for 7:40 pm ET.

How can I access the BridgeBio Pharma webcast?

You can access the live webcast on the 'Events & Presentations' page of the BridgeBio website.

Is there a replay available for the BridgeBio Pharma presentation?

Yes, a replay of the presentation will be available for 90 days following the event.

What is the focus of BridgeBio Pharma's research?

BridgeBio Pharma focuses on developing medicines for genetic diseases and cancers with clear genetic drivers.